ABC | Volume 110, Nº3, March 2018

Review Article Ket et al Practical Implications of Myocardial Viability Studies Arq Bras Cardiol. 2018; 110(3):278-288 46. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445-53. 47. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascularmagnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110(12):1535-41. 48. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1):215-23. 49. Gerber BL, Rousseau MF, Ahn SA, le Polain de Waroux JB, Pouleur AC, Phlips T, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol. 2012;59(9):825-35 50. Sara L, Szarf G, Tachibana A, Shiozaki AA, Villa AV, de Oliveira AC, et al; Sociedade Brasileira de Cardiologia, Colegio Brasileiro de Radiologia. [II Guidelines on Cardiovascular Magnetic Resonance and Computed Tomography of the Brazilian Society of Cardiology and the Brazilian College of Radiology]. Arq Bras Cardiol. 2014;103(6 Suppl 3):1-86. 51. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105(2):162-7. 52. Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga- NODAGA-RGD is a suitable substitute for 18FGalacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39(6):777-84. 53. Higuchi T, Nekolla SG, Jankaukas A, Weber AW, Huisman MC, Reder S, et al. Characterization of normal and infarcted rat myocardium using a combination of small-animal PET and clinical MRI. J Nucl Med. 2007;48(2):288-94. 54. Panza JA, Dilsizian V, Laurienzo JM, Curiel RV, Katsiyiannis PT. Relation between thallium uptake and contractile response to dobutamine: implications regarding myocardial viability in patients with chronic coronary arterydiseaseand leftventriculardysfunction.Circulation.1995;91(4):990-8. 55. SadeghianH,Majd-Ardakani J,Lotfi-TokaldanyM, JahangiriC,FathollahiMS. Comparison between dobutamine stress echocardiography andmyocardial perfusion scan to detect viablemyocardium in patients with coronary artery disease and low ejection fraction. Hellenic J Cardiol. 2009;50(1):45-51. 56. Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart. 1998;79(3):281-8. 57. Barrington SF, Chambers J, Hallett WA, O’DohertyMJ, Roxburgh JC, Nunan TO. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging. 2004;31(3):355-61. 58. Rahimtoola SH. Concept and evaluation of hibernatingmyocardium. Annu Rev Med. 1999;50:75-86. 59. Beller GA, Ragosta M. Extent of myocardial viability in regions of left ventricular dysfunction by rest-redistribution thallium-201 imaging: a powerful predictor of outcome.; J Nucl Cardiol. 1998;5(4):445-8. 60. Ramani K, Judd RM, Holly TA, Parrish TB, Rigolin VH, Parker MA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction.; Circulation. 1998;98(24):2687-94. 61. LeeVS,ResnickD,TiuSS,Sanger JJ,NazzaroCA, IsraelGM, etal.MR imaging evaluation of myocardial viability in the set of equivocal SPECT results with 99m Tc-sestamibi. Radiology. 2004;230(1):191-7. 62. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983;68(4):785-95. 63. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy.; N Engl J Med. 2016;374(16):1511-20. 64. Shah B.N.; Khattar R.S.; Senior R.; The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era.; Eur Heart J 2013;34:1323–36 65. Desideri A.; Cortigiani L.; Christen A.I.; et al.; The extent of perfusion–F18- fluorodeoxyglucose positron emission tomography mismatch determines mortality inmedically treated patients with chronic ischemic left ventricular dysfunction.; J Am Coll Cardiol 2005;46:1264–9. 66. Van Loon, R.B.; Veen G.; Baur L. HB; Kamp O.; Bronzwaer J. GF.; Twisk J. W. R.; Verheugt F. WA; Van Rossum, A. C.; Improved clinical outcome after invasive management of patients with recent myocardial infarction and provenmyocardial viability: primary results of a randomized controlled trial (VIAMI-trial); Trials 2012, 13:1 67. Peter Carson P.; Wertheimer J.; Alan Miller A.; O’Connor C. M.; Ileana L. Pina I. L.; Selzman C.; Sueta C.; She L.; Greene D.; Lee K. L.; Jones R. H.; Velazquez E. J.; for the STICH Investigators; The STICH Trial (Surgical Treatment for Ischemic Heart Failure); JACC: Heart Failure, Vol.1, No. 5, 2013. 68. Beanlands R.S.B.; Nichol G.; Huszti E.; et al.; PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).; J Am Coll Cardiol 2007;50:2002–12. 287